FDA Brief

Warning letters Drugs

FDA warning letter to

Thrivelab Co. dba Thrivelab

MediumIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

What happened

FDA reviewed Thrivelab's website (https://www.thrivelab.com) in March 2026 and found it offering compounded drug products, including semaglutide. FDA said the site's labels show "thrivelab" as if the company made the drugs when it does not, and that promotional claims such as "Same active ingredient as Ozempic®" and "clinically proven to work" imply the compounded products are FDA-approved when they are not. Because of this, FDA says the products are misbranded (misbranded means the labeling or advertising is false or misleading) and shipping them across state lines is a prohibited act.

What FDA found

  1. The website labels name "thrivelab" on the product label, which suggests Thrivelab made the drug when it did not.

    21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]
  2. The site says the products have the "Same active ingredient as Ozempic®" and "Same active ingredient as Wegovy and Ozempic," which implies FDA approval the compounded drugs do not have.

    FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The site claims the products are "clinically proven to work," which FDA says falsely presents the compounded drugs as evaluated for safety and effectiveness.

    FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]
  4. Selling and shipping these misbranded drugs across state lines is a prohibited act.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]
  5. Receiving misbranded drugs in interstate commerce and delivering them is also prohibited.

    FD&C Act § 301(c) [21 U.S.C. § 331(c)]

What FDA wants

Thrivelab must send a written response to FDA's Office of Compounding Quality and Compliance within 15 business days, identifying who makes the compounded drugs, providing sample labeling, and correcting or removing the misleading website claims.

Who should pay attention

  • telehealth companies selling compounded semaglutide or other GLP-1 drugs
  • compounding pharmacies whose products are marketed by partner websites
  • marketing and regulatory reviewers who approve drug claims on company websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low